AAIC 2025 Abstract
Neuroligin fragments as blood‐based biomarkers for early detection of Alzheimer's disease
By Milton Guilherme Forestieri Fernandes, Maxime Pinard, Esen Sokullu, Show 3 more authorsJonathan Brouillette
Study in peopleBiomarkers
Abstract
Background: Alzheimer's disease (AD) progresses slowly, with advanced neurodegeneration already present by the time clinical symptoms appear. To enhance the effectiveness of potential treatments, biomarkers that can detect the disease in its early stage are needed. Neuroligin (NLGN) is present in synapses, which are affected early in AD.
